Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy & Safety of Fluoroquinolone-Based Brucellosis Regimens (BRUCE)
NCT07779629 · The First Affiliated Hospital of Shihezi University · NA · withdrawn · last registry update 2026-10-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This original trial NCT07779629 was withdrawn before any participant enrollment. The protocol was split into two independent new trials: NCT07887126 and NCT07887152. These two new trials have separate IRB approvals and will be conducted and analyzed” | – | Registry record, The First Affiliated Hospital of Shihezi University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MMP7 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-20Phase 3 first posted: National Institute of Allergy and Infectious Diseases (NIAID), Doxycycline hyclate + Standard of Care for STI prevention (NCT07884240)
- 2026-09-09Phase 3 first posted: Reham Abdelkader Elkhouly, Bismuth added on triple therapy + Quadruple therapy (NCT07810985)
- 2026-07-13Results posted on the registry: PolyPid Ltd., D-PLEX (NCT04411199)
- 2026-06-30Results posted on the registry: PolyPid Ltd., D-PLEX (NCT03558984)
- 2026-06-30Also stopped (terminated): PolyPid Ltd., D-PLEX (NCT03558984)
- 2026-06-22Phase 3 first posted: HIV Prevention Trials Network, HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA + STI PEP - Doxycycline as Doxy-PEP (NCT07658976)
- 2026-06-03Results posted on the registry: Centers for Disease Control and Prevention, ciprofloxacin + doxyxcycline (NCT01243437)
- 2026-06-03Results posted on the registry: Hawaii Pacific Health, Doxycycline + Placebo (NCT01917721)
- 2026-05-01Results posted on the registry: Emory University, Doxycycline (NCT06545656)
- 2026-04-22Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Metformin Hydrochloride + Doxycycline (NCT02874430)
- 2026-04-22Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Metformin Hydrochloride + Doxycycline (NCT02874430)
- 2026-04-13Results posted on the registry: University of Washington, Doxycycline (NCT06582966)
- 2026-04-01Results posted on the registry: Emory University, Offering of on-demand oral PrEP + Offering of STI PEP (NCT05072093)
- 2026-02-27Also stopped (withdrawn): Campbell Clinic, Doxycycline Injection (NCT07024654)
- 2026-02-25Results posted on the registry: National Taiwan University Hospital, Doxycycline + Ceftriaxone (NCT05980871)
- 2026-02-25Also stopped (terminated): National Taiwan University Hospital, Doxycycline + Ceftriaxone (NCT05980871)
- 2026-01-29Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Metformin Hydrochloride + Doxycycline (NCT03076281)
- 2026-01-29Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Metformin Hydrochloride + Doxycycline (NCT03076281)
- 2026-01-14Also stopped (withdrawn): Tourcoing Hospital, Reduction in the duration of antibiotic therapy 3 weeks or 6 weeks (NCT05074147)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision